Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Gang Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9391-6242; OpenAlex author ID A5080841434, A5143870044. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 18)
Trials
0
Grants
0
Labs led
2
Collaborators
60
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 5 papers · 2014: 2 papers · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 26

  1. Targeting Lactate-Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD-1 Blockade. Last author DOI 10.1002/advs.76008↗
  2. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Last author DOI 10.1038/s41388-021-01960-w↗
  3. LncRNA ZNFTR functions as an inhibitor in pancreatic cancer by modulating ATF3/ZNF24/VEGFA pathway. Last author DOI 10.1038/s41419-021-04119-3↗
  4. LncRNA-ZFAS1 Induces Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells During Nutrient Deprivation by Promoting AMPK-Mediated Phosphorylation and St… Last author DOI 10.21203/rs.3.rs-875697/v1↗
  5. A reciprocal feedback of Myc and lncRNA MTSS1-AS contributes to extracellular acidity-promoted metastasis of pancreatic cancer. Last author DOI 10.7150/thno.49147↗
  6. Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Last author DOI 10.1158/0008-5472.can-18-0419↗
  7. Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Last author DOI 10.7150/thno.30988↗
  8. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Last author DOI 10.7150/thno.34559↗
  9. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Last author DOI 10.1038/s41388-017-0082-2↗
  10. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Last author DOI 10.1038/s41388-018-0382-1↗
  11. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. Last author DOI 10.1038/s41419-017-0158-5↗
  12. ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca2+/RhoA pathway. Last author DOI 10.1038/cddis.2017.189↗
  13. MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Last author DOI 10.1158/1535-7163.mct-15-0877↗
  14. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Last author DOI 10.18632/oncotarget.6830↗
  15. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  16. Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Last author DOI 10.1038/gt.2015.39↗
  17. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Last author DOI 10.18632/oncotarget.5350↗
  18. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  19. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Last author DOI 10.1016/j.canlet.2014.08.007↗
  20. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Last author DOI 10.1111/cas.12364↗
  21. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. First author DOI 10.1016/j.pan.2013.01.001↗
  22. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Co-author DOI 10.1158/1535-7163.mct-12-0534-t↗
  23. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Co-author DOI 10.1158/1535-7163.mct-13-0296↗
  24. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Co-author DOI 10.1245/s10434-012-2364-9↗
  25. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. Co-author DOI 10.1371/journal.pone.0073803↗
  26. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Co-author DOI 10.1038/gt.2011.81↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunyou Wang · 18 shared papers, 2013–2021 · strength 1.00
  2. Zhu Zeng · 10 shared papers, 2016–2021 · strength 0.87
  3. Yuhang Hu · 6 shared papers, 2019–2026 · strength 0.76
  4. Fengyu Xu · 8 shared papers, 2018–2021 · strength 0.75
  5. Shichang Deng · 14 shared papers, 2013–2019 · strength 0.70
  6. Shi-Jiang Deng · 10 shared papers, 2014–2019 · strength 0.66
  7. Shuai Zhu · 10 shared papers, 2013–2021 · strength 0.61
  8. Mingliang Liu · 7 shared papers, 2016–2019 · strength 0.51
  9. Ye Zeng · 6 shared papers, 2018–2021 · strength 0.49
  10. Xiang Li · 10 shared papers, 2013–2018 · strength 0.48
  11. Qi Qin · 9 shared papers, 2011–2018 · strength 0.35
  12. Yan Jin · 5 shared papers, 2014–2018 · strength 0.29
  13. Wenfeng Zhuo · 1 shared paper, 2026 · strength 0.25
  14. Jungang Zhang · 6 shared papers, 2013–2014 · strength 0.21
  15. Wei Li · 2 shared papers, 2020–2021 · strength 0.21
  16. Peng Xu · 2 shared papers, 2020–2021 · strength 0.19
  17. Qiang Li · 2 shared papers, 2018–2019 · strength 0.15
  18. Defei Hong · 3 shared papers, 2014–2016 · strength 0.11
  19. Yi Niu · 2 shared papers, 2013–2018 · strength 0.10
  20. Tao Yin · 3 shared papers, 2011–2015 · strength 0.10
  21. Qiang Li · 1 shared paper, 2019 · strength 0.09
  22. Shuai Zhu · 2 shared papers, 2015–2016 · strength 0.09
  23. Zhi Fang · 1 shared paper, 2020 · strength 0.09
  24. Wei Li · 1 shared paper, 2019 · strength 0.08
  25. Quanxing Ni · 2 shared papers, 2015–2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.